STOCK TITAN
  1. Home
  2. Sec-filings
  3. ABCL
  4. [Form 4] AbCellera Biologics Inc. Insider Trading Activity

AbCellera (ABCL) director Stephen Quake awarded 111,701 share options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

AbCellera Biologics Inc. director Stephen Quake received a grant of 111,701 share options giving the right to buy an equal number of common shares at an exercise price of $5.27 per share. After this grant, Quake holds share options for a total of 306,633 common shares.

The options vest and become exercisable at the company’s 2027 Annual General Meeting, provided Quake continues to serve the company through that date. This is a compensation-related award rather than an open-market stock trade.

Positive

  • None.

Negative

  • None.
Insider Quake Stephen
Role null
Type Security Shares Price Value
Grant/Award Share option (right to buy) 111,701 $0.00 --
Holdings After Transaction: Share option (right to buy) — 306,633 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Share options granted 111,701 options Grant of share options to director Stephen Quake
Exercise price $5.27 per share Exercise price of newly granted options
Total options after grant 306,633 options Derivative holdings following the reported grant
Vesting date 2027 Annual General Meeting Options vest at the 2027 AGM, subject to continuous service
Expiration date June 11, 2036 Expiration of the newly granted share options
Share option (right to buy) financial
"security_title: "Share option (right to buy)""
Common Shares financial
"underlying_security_title: "Common Shares""
Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.
Annual General Meeting financial
"vest and become exercisable at the 2027 Annual General Meeting"
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Quake Stephen
(Last)(First)(Middle)
ABCELLERA BIOLOGICS INC
150 W 4TH AVENUE
(Street)
VANCOUVER
(City)(State)(Zip)
BRITISH COLUMBIA, CANADA
(Country)		2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share option (right to buy)$5.2706/11/2026AV111,70106/10/2027(1)06/11/2036Common Shares111,701$0306,633D
Explanation of Responses:
1. The shares subject to such option vest and become exercisable at the 2027 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date.
Remarks:
Tryn Stimart, attorney-in-fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did AbCellera Biologics (ABCL) director Stephen Quake report on this Form 4?

Stephen Quake reported receiving a grant of 111,701 share options. Each option allows him to buy one AbCellera common share at an exercise price of $5.27, increasing his total outstanding options to 306,633 common-share equivalents.

Is Stephen Quake buying or selling AbCellera (ABCL) shares in this filing?

He is not buying or selling shares on the open market. The Form 4 shows a compensation-related grant of 111,701 share options, giving him the right to buy AbCellera common shares later at $5.27 per share.

When do Stephen Quake’s new AbCellera (ABCL) share options vest and become exercisable?

The newly granted options vest and become exercisable at AbCellera’s 2027 Annual General Meeting. Vesting is conditional on Quake’s continuous service to the company through that date, according to the footnote in the Form 4.

What is the exercise price and expiration date of Stephen Quake’s new AbCellera options?

The 111,701 granted share options have an exercise price of $5.27 per common share and expire on June 11, 2036. Quake can exercise them after vesting, subject to the vesting condition tied to the 2027 Annual General Meeting.

How many AbCellera (ABCL) share options does Stephen Quake hold after this grant?

Following this grant, Stephen Quake holds options covering 306,633 AbCellera common shares. This total includes the newly granted 111,701 options and reflects his aggregate derivative position reported in this Form 4 filing.